Notice Pursuant to the National Cooperative Research and Production Act of 1993-Rapid Response Partnership Vehicle, 52095-52096 [2024-13625]

Download as PDF Federal Register / Vol. 89, No. 120 / Friday, June 21, 2024 / Notices of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on July 17, 2015 (80 FR 42537). The last notification was filed with the Department on January 25, 2024. A notice was published in the Federal Register pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 26926). DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Alliance for OpenUSD Series LLC ddrumheller on DSK120RN23PROD with NOTICES1 BILLING CODE P Notice Pursuant to the National Cooperative Research and Production Act of 1993—Rapid Response Partnership Vehicle BILLING CODE 4410–11–P Notice is hereby given that, on April 25, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Alliance for OpenUSD Series LLC (‘‘AOUSD’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing additions or changes to its standards development activities. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, AOUSD has formed two additional Working Groups (‘‘WGs’’) in March 2024: a Materials WG and a Geometry WG. The Materials WG will standardize the description of materials in OpenUSD. Its initial focus and first deliverable will be the USD Material Interchange Specification, which will comprise a set of patterns and BSDF nodes comprising the MaterialX standard libraries. The Geometry WG will define and evolve the strategy for the description of 3D geometry in OpenUSD. Its first deliverable will be the USD Transformable 3D Geometry Specification that will describe the surfaces and volume representations, spatial transformations, rules of determining primary visibility, and other properties required for imaging those representations. On October 30, 2023, AOUSD filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Jkt 262001 [FR Doc. 2024–13636 Filed 6–20–24; 8:45 am] Antitrust Division [FR Doc. 2024–13659 Filed 6–20–24; 8:45 am] 17:46 Jun 20, 2024 Suzanne Morris, Deputy Director, Civil Enforcement Operations, Antitrust Division. DEPARTMENT OF JUSTICE Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. VerDate Sep<11>2014 Act on December 15, 2023 (88 FR 86939). Notice is hereby given that, on April 12, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Rapid Response Partnership Vehicle (‘‘RRPV’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, A-line, Inc., Signal Hill, CA; ANP Technologies, Inc., Newark, DE; ARNAV Biotech Corp., Atlanta, GA; Action Medical Technologies LLC, Conshohocken, PA; AmerStem, Inc., Camarillo, CA; American Type Culture Collection, Manassas, VA; Aposense, Ltd., Petach Tikva, ISRAEL; Appili Therapeutics USA, Inc., Frederick, MD; Aptitude Medical Systems, Goleta, CA; Arranta Bio MA LLC, Watertown, MA; Asha Therapeutics LLC, Tampa, FL; BDO Public Sector LLC, Mclean, VA; BRCR Medical Center, Inc., Plantation, FL; Battelle Memorial Institute, Columbus, OH; BioInfoExperts LLC, Thibodaux, LA; Boost Biopharma, Inc., Amherst, MA; Bracane Company, Plano, TX; Capra Biosciences, Inc., Manassas, VA; Capricor Therapeutics, Inc., San Diego, CA; CellCarta Biosciences, Inc., Montreal, CANADA; Cerba Research USA, Inc., Lake Success, NY; Clarametyx Biosciences, Inc., Columbus, OH; Clarus Biologics, Inc., Chapel Hill, NC; Cue Health, Inc., San Diego, CA; D’Angelo Technologies LLC, Beavercreek, OH; DEKA Research & Development Corp., Manchester, NH; Datavant, Phoenix, AZ; Deutsches Zentrum für Infektionsforschung e.V., Braunschweig, GERMANY; Diagnostic Consulting Network LLC dba DCN Diagnostics, Carlsbad, CA; Diasorin Molecular, Cypress, CA; EMD Millipore dba MilliporeSigma, Burlington, MA; PO 00000 Frm 00086 Fmt 4703 Sfmt 4703 52095 Ethris GmbH, Planegg, GERMANY; FONDAZIONE BIOTECNOPOLO DI SIENA, SIENA, ITALY; Flagship Labs, Cambridge, MA; Fred Hutchinson Cancer Center, Seattle, WA; Genentech, South San Francisco, CA; GiwoTech, Inc., Wilmington, DE; Global Action Alliance, Inc., Ashburn, VA; HDT Bio Corp., Seattle, WA; Hope Biosciences, Sugar Land, TX; IQVIA Government Solutions, Inc., Falls Church, VA; Icahn School of Medicine at Mount Sinai, New York, NY; InBios International, Seattle, WA; Injection Safety Industries LLC, Bowling Green, KY; Inovio Pharmaceuticals, Plymouth Meeting, PA; Integrated Biotherapeutics LLC dba IBT Bioservices, Rockville, MD; LTS Lohmann Therapie-Systeme AG, Andernach, GERMANY; Labcorp, Burlington, NC; Labcorp-Monogram Biosciences, South San Francisco, CA; Lyndra Therapeutics, Inc., Watertown, MA; Major, Inc., Los Angeles, CA; MalarVx, Inc., Seattle, WA; Mirimus, Inc., Brooklyn, NY; Nature’s Toolbox, Inc., Rio Rancho, NM; New Horizon Biotech, Inc., Nazareth, PA; OncoC4, Inc., Rockville, MD; PIF Partners LLC, Englewood, NJ; PharmaJet, Inc., Golden, CO; Precision for Medicine, Inc., Frederick, MD; Revvity Health Sciences, Hopkinton, MA; Rocketvax, Ltd., Basel, SWITZERLAND; Selva Therapeutics, Inc., San Mateo, CA; Sentio BioSciences LLC, Maryland Heights, MO; Solaris Vaccines, Inc., Fort Collins, CO; Spring Discovery, Inc., San Carlos, CA; Technical Resources International, Inc., Bethesda, MD; The Emmes Company LLC, Rockville, MD; The Pandemic Institute (Legally hosted by the University of Liverpool), Liverpool, UNITED KINGDOM; Tonix Pharmaceutical Holdings, Chatham, NJ; Trawsfynydd Therapeutics, Inc., Rockville, MD; US Specialty Formulations LLC, Allentown, PA; Univercells S.A., Brussels, BELGIUM; VaxForm LLC, Bethlehem, PA; VisMederi Srl, Siena, ITALY; Vyriad, Inc., Rochester, MN; Walgreen Co., Deerfield, IL; Yourbio Health, Medford, MA; and iosBio, Ltd., Haywards Heath, UNITED KINGDOM, have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and RRPV intends to file additional written notifications disclosing all changes in membership. On January 5, 2024, RRPV filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal E:\FR\FM\21JNN1.SGM 21JNN1 52096 Federal Register / Vol. 89, No. 120 / Friday, June 21, 2024 / Notices 6(b) of the Act on January 6, 2016 (81 FR 513). The last notification was filed with the Department on January 5, 2024. A notice was published in the Federal Register pursuant to section 6(b) of the Act on February 06, 2024 (89 FR 8244). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. DEPARTMENT OF JUSTICE Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. DEPARTMENT OF JUSTICE Antitrust Division [FR Doc. 2024–13608 Filed 6–20–24; 8:45 am] Antitrust Division Register pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 26928). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2024–13625 Filed 6–20–24; 8:45 am] BILLING CODE P ddrumheller on DSK120RN23PROD with NOTICES1 Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium Notice is hereby given that, on April 2, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Medical CBRN Defense Consortium (‘‘MCDC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Alamgir Research Inc DBA ARIScience, Wayland, MA; American Additive Manufacturing LLC, Horsham, PA; Amyris Inc, Emeryville, CA; Arnasi 701 LLC, Woburn, MA; Columbus Nanoworks, Columbus, OH; Genetic Networks LLC, Miami Beach, FL; Radiation Monitoring Devices Inc, Watertown, MA; Repurposed Therapeutics Inc, Saint Louis, MO, have been added as parties to this venture. Also, Clarifia Inc, New York, NY; Conductive Technologies Inc, York, PA; Government Scientific Source, Reston, VA; Kleo Pharmaceuticals, New Haven, CT; Locus Biosciences, Morrisville, NC; Pertexa Healthcare Technologies, Ridgecrest, CA; SX2 Technologies LLC, Port Washington, WI; and Trauma Insight LLC dba LumaBridge LLC, San Antonio, TX, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MCDC intends to file additional written notifications disclosing all changes in membership. On November 13, 2015, MCDC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section VerDate Sep<11>2014 17:46 Jun 20, 2024 Jkt 262001 BILLING CODE P Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—APA—The Engineered Wood Association Notice is hereby given that, on April 4, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), APA—The Engineered Wood Association (‘‘APA— The Engineered Wood Association’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the name and principal place of business of the standards development organization and (2) the nature and scope of its standards development activities. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to section 6(b) of the Act, the name and principal place of business of the standards development organization is: APA—The Engineered Wood Association, Tacoma, WA. The nature and scope of APA—The Engineered Wood Association’s standards development activities are: the development, maintenance, and updating of standards for wood and engineered wood products including but not limited to softwood plywood, oriented strand board (OSB), wood composite panels, plywood siding, structural glued laminated timber (glulam), wood I-joists, structural composite lumber, rim board, and crosslaminated timber. Standards activities also include serving as the sponsor for the standing committees of U.S. Voluntary Product Standard PS 1, Structural Plywood and Voluntary Frm 00087 Fmt 4703 Sfmt 9990 [FR Doc. 2024–13616 Filed 6–20–24; 8:45 am] BILLING CODE P Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cable Television Laboratories, Inc. DEPARTMENT OF JUSTICE PO 00000 Product Standard PS 2, Performance Standard for Wood Structural Panels. Notice is hereby given that, on May 17, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Cable Television Laboratories, Inc. (‘‘CableLabs’’) filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, E. Ritter Communications Holdings, LLC, Wilmington, DE, has been added as a party to this venture. Also, Guangzhou Digital Media Group Co. Limited, Guangzhou, PEOPLE’S REPUBLIC OF CHINA; Guangdong Cable Corporation Limited, Guangzhou, PEOPLE’S REPUBLIC OF CHINA; and Videotron Ltée, Montreal, Quebec, CANADA, have been terminated as parties to this venture. No other changes have been made in either the membership or planned activity of the venture. Membership in this venture remains open, and CableLabs intends to file additional written notifications disclosing all changes in membership. On August 8, 1988, CableLabs filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on September 7, 1988 (53 FR 34593). The last notification was filed with the Department on March 31, 2022. A notice was published in the Federal Register pursuant to section 6(b) of the Act on May 13, 2022 (87 FR 29385). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2024–13656 Filed 6–20–24; 8:45 am] BILLING CODE P E:\FR\FM\21JNN1.SGM 21JNN1

Agencies

[Federal Register Volume 89, Number 120 (Friday, June 21, 2024)]
[Notices]
[Pages 52095-52096]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-13625]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Rapid Response Partnership Vehicle

    Notice is hereby given that, on April 12, 2024, pursuant to section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership 
Vehicle (``RRPV'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Specifically, A-line, Inc., Signal Hill, CA; ANP Technologies, 
Inc., Newark, DE; ARNAV Biotech Corp., Atlanta, GA; Action Medical 
Technologies LLC, Conshohocken, PA; AmerStem, Inc., Camarillo, CA; 
American Type Culture Collection, Manassas, VA; Aposense, Ltd., Petach 
Tikva, ISRAEL; Appili Therapeutics USA, Inc., Frederick, MD; Aptitude 
Medical Systems, Goleta, CA; Arranta Bio MA LLC, Watertown, MA; Asha 
Therapeutics LLC, Tampa, FL; BDO Public Sector LLC, Mclean, VA; BRCR 
Medical Center, Inc., Plantation, FL; Battelle Memorial Institute, 
Columbus, OH; BioInfoExperts LLC, Thibodaux, LA; Boost Biopharma, Inc., 
Amherst, MA; Bracane Company, Plano, TX; Capra Biosciences, Inc., 
Manassas, VA; Capricor Therapeutics, Inc., San Diego, CA; CellCarta 
Biosciences, Inc., Montreal, CANADA; Cerba Research USA, Inc., Lake 
Success, NY; Clarametyx Biosciences, Inc., Columbus, OH; Clarus 
Biologics, Inc., Chapel Hill, NC; Cue Health, Inc., San Diego, CA; 
D'Angelo Technologies LLC, Beavercreek, OH; DEKA Research & Development 
Corp., Manchester, NH; Datavant, Phoenix, AZ; Deutsches Zentrum 
f[uuml]r Infektionsforschung e.V., Braunschweig, GERMANY; Diagnostic 
Consulting Network LLC dba DCN Diagnostics, Carlsbad, CA; Diasorin 
Molecular, Cypress, CA; EMD Millipore dba MilliporeSigma, Burlington, 
MA; Ethris GmbH, Planegg, GERMANY; FONDAZIONE BIOTECNOPOLO DI SIENA, 
SIENA, ITALY; Flagship Labs, Cambridge, MA; Fred Hutchinson Cancer 
Center, Seattle, WA; Genentech, South San Francisco, CA; GiwoTech, 
Inc., Wilmington, DE; Global Action Alliance, Inc., Ashburn, VA; HDT 
Bio Corp., Seattle, WA; Hope Biosciences, Sugar Land, TX; IQVIA 
Government Solutions, Inc., Falls Church, VA; Icahn School of Medicine 
at Mount Sinai, New York, NY; InBios International, Seattle, WA; 
Injection Safety Industries LLC, Bowling Green, KY; Inovio 
Pharmaceuticals, Plymouth Meeting, PA; Integrated Biotherapeutics LLC 
dba IBT Bioservices, Rockville, MD; LTS Lohmann Therapie-Systeme AG, 
Andernach, GERMANY; Labcorp, Burlington, NC; Labcorp-Monogram 
Biosciences, South San Francisco, CA; Lyndra Therapeutics, Inc., 
Watertown, MA; Major, Inc., Los Angeles, CA; MalarVx, Inc., Seattle, 
WA; Mirimus, Inc., Brooklyn, NY; Nature's Toolbox, Inc., Rio Rancho, 
NM; New Horizon Biotech, Inc., Nazareth, PA; OncoC4, Inc., Rockville, 
MD; PIF Partners LLC, Englewood, NJ; PharmaJet, Inc., Golden, CO; 
Precision for Medicine, Inc., Frederick, MD; Revvity Health Sciences, 
Hopkinton, MA; Rocketvax, Ltd., Basel, SWITZERLAND; Selva Therapeutics, 
Inc., San Mateo, CA; Sentio BioSciences LLC, Maryland Heights, MO; 
Solaris Vaccines, Inc., Fort Collins, CO; Spring Discovery, Inc., San 
Carlos, CA; Technical Resources International, Inc., Bethesda, MD; The 
Emmes Company LLC, Rockville, MD; The Pandemic Institute (Legally 
hosted by the University of Liverpool), Liverpool, UNITED KINGDOM; 
Tonix Pharmaceutical Holdings, Chatham, NJ; Trawsfynydd Therapeutics, 
Inc., Rockville, MD; US Specialty Formulations LLC, Allentown, PA; 
Univercells S.A., Brussels, BELGIUM; VaxForm LLC, Bethlehem, PA; 
VisMederi Srl, Siena, ITALY; Vyriad, Inc., Rochester, MN; Walgreen Co., 
Deerfield, IL; Yourbio Health, Medford, MA; and iosBio, Ltd., Haywards 
Heath, UNITED KINGDOM, have been added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and RRPV intends to file additional 
written notifications disclosing all changes in membership.
    On January 5, 2024, RRPV filed its original notification pursuant 
to section 6(a) of the Act. The Department of Justice published a 
notice in the Federal

[[Page 52096]]

Register pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 
26928).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-13625 Filed 6-20-24; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.